Navigation Links
Research on New Treatment for Neglected Disease Published in The,New England Journal of Medicine

SAN FRANCISCO & NEW DELHI, India--(BUSINESS WIRE)--Jun 21, 2007 - The Institute for OneWorld Health, a US-based non-profit pharmaceutical company, today announced that Phase 3 research related to its first approved drug product, Paromomycin IM Injection (Paromomycin), was published in the current issue of The New England Journal of Medicine (NEJM). This clinical trial shows that the medicine paromomycin is safe, effective, and well suited to curing visceral leishmaniasis (VL), the world's second most deadly parasitic disease after malaria.

The Institute for OneWorld Health, working closely with the Indian Council for Medical Research (ICMR) sponsored the clinical trial in collaboration with the Special Programme for Research and Training in Tropical Diseases (TDR), a Geneva-based international organization sponsored by UNICEF, UNDP, the World Bank and the World Health Organization. The clinical trial was established with funding from the Bill & Melinda Gates Foundation.

Gland Pharma Limited, the Hyderabad, India-based drug manufacturer, working with OneWorld Health and other collaborators, received regulatory approval from the Drug-Controller General - India (DCGI) for Paromomycin IM Injection as a treatment for VL on August 31, 2006. Gland Pharma has agreed to act as the global manufacturer of Paromomycin to ensure access to all those that need it, and at a markedly reduced cost -- currently, approximately $10 USD per 21-day course of therapy.

"The results of this study underscore the potential of Paromomycin to treat VL -- and save lives -- at very low cost and in safe and practical ways," said Dr. Ahvie Herskowitz, co-founder and chief medical officer of the Institute for OneWorld Health. "This research is essential to increasing access to new therapies for this neglected disease, also known as kala-azar and black fever."

With approximately 500,000 new cases occurring annually wo rldwide, VL primarily afflicts the rural resource-poor populations in India, Nepal, Bangladesh, Sudan and Brazil, where affordable new therapies are needed.

The print issue of the publication will be available in the June 21, 2007, issue of the NEJM. The article, "Injectable Paromomycin for Visceral Leishmaniasis in India," was authored by Shyam Sundar, M.D., T.K. Jha, M.D., Chandreshwar P. Thakur, M.D., Prabhat K. Sinha, M.D., and Sujit K. Bhattacharya, M.D., Principal Investigators in the Phase 3 clinical trial. The article is accessible online, and can be found at under the "Current Issue" section of the Web site.

The researchers conducted a randomized, controlled, phase 3 study comparing Paromomycin, an aminoglycoside, and amphotericin B, the present standard of care in Bihar, India. Paromomycin was shown to be noninferior to amphotericin B with a final cure rate of 94.6% vs. 98.8% for amphotericin. Paromomycin also had an acceptable safety profile, which included mild injection-site pain in 55% of patients and transient increases in liver function values in 6% of patients. The NEJM reports that Paromomycin may be advantageous because of the shorter duration of its administration (21 days versus 30 days for amphotericin B), its demonstrated safety and efficacy in pediatric patients (96%) and in patients who failed to be cured with other medicines (98%).

The NEJM article concluded, "The healthcare delivery system in India is well suited to the intramuscular administration of Paromomycin under directly observed therapy, and the local manufacture of Paromomycin in India, potentially at a very low cost, makes this an approachable therapy in the setting of limited resources."

Earlier this year, the World Health Organization (WHO) selected Paromomycin IM Injection for inclusion on its Model List for Essential Medicines. The WHO List of Essential Medicines provides a model for countries to select medicines addressing public heal th priorities according to quality, safety and efficacy standards.

About Visceral Leishmaniasis

VL is a systemic infection caused by various species of Leishmania parasites. The infection is transmitted by sandflies and causes chronic fever, weight loss, splenomegaly, hepatomegaly and anemia. Left untreated, VL is nearly always fatal. VL currently occurs in 62 countries, primarily in the developing world. Of the approximately 500,000 new cases of VL occurring annually, 90% are found in just five countries: India, Bangladesh, Nepal, Sudan and Brazil. South Asia carries 70% of all estimated new VL cases per year worldwide, with India alone carrying 50% of all new cases. The most affected state in India is Bihar, but VL is also endemic in the states of Jharkand, West Bengal, and Uttar Pradesh.

About Paromomycin Phase 3 Clinical Trial

The approval of Paromomycin IM Injection in India is based on data from a large Phase 3 multi-center, randomized, controlled study of 667 adult and pediatric patients conducted in Bihar State, India over a 17-month period from June 2003 until November 2004. Paromomycin was shown to cure 94.6% of patients with VL, with an acceptable side effect profile. The most common adverse reaction among patients treated with Paromomycin was mild pain at the injection site.

About Paromomycin IM Injection

An off-patent aminoglycoside antibiotic, paromomycin is an established drug with an extensive and well-characterized safety profile. Paromomycin IM Injection is now available from Gland Pharmaceuticals (Hyderabad, India) for the first time as a new treatment of VL in India as a once-a-day injection for 21 days. The cost of Paromomycin IM Injection is significantly lower than other currently approved VL therapies.

About the Institute for OneWorld Health

The Institute for OneWorld Health, the first US non-profit pharmaceutical company, develops safe, effective and affordable medicines for people with neglected diseases of the developing world. The Institute for OneWorld Health, headquartered in San Francisco, California, USA, is a tax-exempt 501(c)(3) US corporation. ( Media resources are available at


For the Institute for OneWorld Health
Pat Reilly, 415-277-6971 (U.S.)
Nymphia Vishin, (+91) 989-921-6600 (India)


Related medicine technology :

1. NIEHS Researchers Identify Enzyme Critical in DNA Replication
2. Stanford Researchers Find Brain Pathway of Depression in Rats
3. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
4. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
5. Researchers Discover Method for Identifying How Cancer Evades the Immune System
6. Infertile Voice Supports Stem Cell Research: RESOLVE Calls for Patient Options in Using Frozen Embryos
7. Fact Sheet: Advancing Stem Cell Research While Respecting Moral Boundaries
8. President Bush Ignores Americas Plea for Support of Stem Cell Research
9. Researchers Discover Gene For Rare Skin Disorder
10. The Christopher and Dana Reeve Foundation Expresses Disappointment Over President Bushs Veto of the Stem Cell Research Enhancement Act
11. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015  Family Rentals, a ... announced the launch of their newly designed, mobile-responsive ... --> Logo ... --> --> Now, renting essential ... and vacation, just got a whole lot easier ...
(Date:11/24/2015)... --> --> Opportunities ... and PPAR Agonists cholesterol-lowering drugs market ? ... rates? This visiongain report shows you potential ... there. ,  ,Our 199-page report provides 153 tables, charts, ... industry and the future market prospects. Our new study ...
(Date:11/24/2015)... , Nov. 24, 2015  Boston Scientific Corporation (NYSE: ... Oppenheimer 26th Annual Healthcare Conference on December 8, in ... Susie Lisa , vice president, Investor Relations, will participate ... beginning at approximately 8:35 a.m. ET. --> ... in a 30-minute question-and-answer session with the host analyst ...
Breaking Medicine Technology:
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... it has been designated an Aetna Institute of Quality® Bariatric Surgery Facility for ... the quality and cost of health care services available to its members to ...
(Date:11/24/2015)... M.D. (PRWEB) , ... November 24, 2015 , ... ... new award for its exceptional customer service: the TrustDale certification. The award recognizes ... The Baltimore stone honing , tile and grout, and hard surface restoration ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Autism Speaks, ... the global movement driven by social media and the generosity of people around the ... encourage their social media networks to give – and share the personal stories behind ...
(Date:11/24/2015)... ... 2015 , ... All her life, Don Peck’s mother wondered if she was a descendant of ... been. After a 25-year search for information, Don and his aunt discovered that she ... name. Turns out, it was Don’s father who was descended from not one, but ...
(Date:11/24/2015)... ... November 24, 2015 , ... Dehydration, defined as a loss of body ... in the hot sun, and heat stroke and death will quickly follow. A normal ... Sharon Kleyne. Every cell, system and structure requires water to function properly. Kleyne, who ...
Breaking Medicine News(10 mins):